Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, the ProVal-MS study.
Bayas A, Mansmann U, Ön BI, Hoffmann VS, Berthele A, Mühlau M, Kowarik MC, Krumbholz M, Senel M, Steuerwald V, Naumann M, Hartberger J, Kerschensteiner M, Oswald E, Ruschil C, Ziemann U, Tumani H, Vardakas I, Albashiti F, Kramer F, Soto-Rey I, Spengler H, Mayer G, Kestler HA, Kohlbacher O, Hagedorn M, Boeker M, Kuhn K, Buchka S, Kohlmayer F, Kirschke JS, Behrens L, Zimmermann H, Bender B, Sollmann N, Havla J, Hemmer B; ProVal-MS study group.
Bayas A, et al.
Neurol Res Pract. 2024 Mar 7;6(1):15. doi: 10.1186/s42466-024-00310-x.
Neurol Res Pract. 2024.
PMID: 38449051
Free PMC article.